Gastroenterology, Public Health Chapel Hill, North Carolina, United States of America
Connect with the speaker?
Evan Dellon, MD, MPH, professor of medicine, was recognized as a Top Ten Clinical Research Achievement Awardee for his study titled “Anti-Selig-8 Antibody for Eosinophilic Gastritis and Duodenitis,” which was published in the New England Journal of Medicine last fall. Eosinophilic gastrointestinal disorders are an under-recognized cause of gastrointestinal illness. Increasing in incidence for reasons that are unclear, eosinophilic GI disorders have no FDA-approved therapies. Dellon and his colleagues performed a randomized controlled trial of lirentelimab, an anti-Siglec-8 antibody, in patients with eosinophilic gastritis and duodenitis. This monoclonal antibody depletes eosinophils and inhibits mast cells, which are thought to be critical in the pathogenesis of these diseases.
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)